Laura Lee Godlewski Net Worth

Ms. Laura Lee Godlewski biography

Laura Lee Godlewski is the Sr. VP of Fin. & Admin. at HTG Molecular Diagnostics Inc.

How old is Ms Godlewski?

Ms Godlewski is 41, she's been the Sr. VP of Fin. & Admin. of HTG Molecular Diagnostics Inc since . There are 16 older and no younger executives at HTG Molecular Diagnostics Inc. The oldest executive at HTG Molecular Diagnostics Inc is Harry George, 71, who is the Independent Director.

What's Ms Godlewski's mailing address?

Laura's mailing address filed with the SEC is C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON, AZ, 85706.

Insiders trading at HTG Molecular Diagnostics Inc

Over the last 9 years, insiders at HTG Molecular Diagnostics Inc have traded over $5,630,772 worth of HTG Molecular Diagnostics Inc stock and bought 1,019,150 units worth $14,128,765 . The most active insiders traders include Plc Gsk, Holdings A/S Novo e Laurence W Lytton. On average, HTG Molecular Diagnostics Inc executives and independent directors trade stock every 64 days with the average trade being worth of $28,039. The most recent stock trade was executed by Stephen Barat on 8 June 2023, trading 888 units of HTGM stock currently worth $710.

What does HTG Molecular Diagnostics Inc do?

about htg molecular diagnostics: headquartered in tucson, arizona, htg's mission is to empower precision medicine at the local level. in 2013 the company commercialized its htg edge instrument platform and a portfolio of rna assays that leverage htg's proprietary nuclease protection chemistry. htg's product offerings have since expanded to include its htg edgeseq product line, which automates sample and targeted library preparation for next-generation sequencing. additional information is available at www.htgmolecular.com.

HTG Molecular Diagnostics Inc executives and stock owners

HTG Molecular Diagnostics Inc executives and other stock owners filed with the SEC include:

• John Lubniewski,
  President, Chief Executive Officer, Director
• John L. Lubniewski,
  Pres, CEO & Director
• Shaun D. McMeans,
  Sr. VP, CFO, Sec. & Treasurer
• Shaun McMeans,
  Chief Financial Officer, Senior Vice President, Treasurer, Secretary
• Byron T. Lawson,
  Sr. VP & Chief Commercial Officer
• Timothy Johnson,
  Executive Chairman of the Board
• Byron Lawson,
  Senior Vice President and Chief Commercial Financial Officer
• Lee McCracken,
  Independent Director
• James LaFrance,
  Independent Director
• Donnie Hardison,
  Independent Director
• Michelle Griffin,
  Independent Director
• Harry George,
  Independent Director
• Ann Hanham,
  Lead Independent Director
• Laura Beggrow,
  Pres of Diagnostics
• Dr. Stephen A. Barat Ph.D.,
  Sr. VP of Therapeutics
• Dr. Marian Navratil Ph.D.,
  Sr. VP of R&D
• Dr. Patrick C. Roche,
  Sr. VP of R&D
• Dr. Debra A. Gordon,
  Sr. VP & Chief Legal Counsel
• Laura Lee Godlewski,
  Sr. VP of Fin. & Admin.
• Dr. Maureen T. Cronin Ph.D.,
  Sr. VP & Chief Scientific Officer
• Christopher P Kiritsy,
  Director
• Stephen Barat,
  Senior VP of Therapeutics
• Debra A Gordon,
  V.P. and Chief Legal Counsel
• Lewis Shuster,
  Director
• Plc Gsk,
  10% owner
• Don M Hardison,
  Director
• Holdings A/S Novo,
  10% owner
• Nv Qiagen,
  10% owner
• Patrick C. Roche,
  SVP Research & Development
• Spaght Ventures Ii Lpfsv Ii...,
  
• Donald W Grimm,
  Director
• Capital Ventures Llc Senour...,
  
• Tim B Johnson,
  Executive Chairman
• Laurence W Lytton,
  10% owner
• Thomas W. Dubensky,
  Director
• Laura Lee Godlewski,
  SVP Finance & Administration